Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $536 | $450 | $184 | $259 |
| % Growth | 19.3% | 144.2% | -29% | – |
| Cost of Goods Sold | $3,613 | $3,039 | $2,548 | $1,457 |
| Gross Profit | -$3,077 | -$2,589 | -$2,364 | -$1,197 |
| % Margin | -573.7% | -575.9% | -1,283.4% | -461.7% |
| R&D Expenses | $0 | $0 | $2,548 | $1,457 |
| G&A Expenses | $2,004 | $2,157 | $226 | $718 |
| SG&A Expenses | $2,004 | $2,157 | $226 | $718 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$2,548 | -$1,457 |
| Operating Expenses | $2,004 | $2,157 | $226 | $718 |
| Operating Income | -$5,081 | -$4,746 | -$2,590 | -$1,916 |
| % Margin | -947.2% | -1,055.6% | -1,406.3% | -738.7% |
| Other Income/Exp. Net | $64 | $127 | -$8 | $50 |
| Pre-Tax Income | -$5,016 | -$4,619 | -$2,598 | -$1,865 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,016 | -$4,619 | -$2,598 | -$1,865 |
| % Margin | -935.2% | -1,027.3% | -1,410.6% | -719.3% |
| EPS | -4.79 | -6.16 | -5.12 | -4 |
| % Growth | 22.2% | -20.3% | -28% | – |
| EPS Diluted | -4.79 | -6.16 | -5.12 | -4.38 |
| Weighted Avg Shares Out | 1,048 | 750 | 507 | 466 |
| Weighted Avg Shares Out Dil | 1,048 | 750 | 508 | 426 |
| Supplemental Information | – | – | – | – |
| Interest Income | $64 | $138 | $2 | $0 |
| Interest Expense | $0 | $11 | $10 | $7 |
| Depreciation & Amortization | $3 | $2 | $0 | $0 |
| EBITDA | -$5,013 | -$4,606 | -$2,588 | -$1,859 |
| % Margin | -934.7% | -1,024.5% | -1,405.4% | -716.7% |